ArticleTranslational cancer research2025
Untargeted metabolomics integrated with SHAP analysis identifies novel biomarkers of oxaliplatin induced peripheral neurotoxicity in gastric cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment and validation of a prognostic model based on liquid-liquid phase separation-related genes in gastric cancer.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxaliplatin-induced peripheral neuropathy (OIPN) is an important adverse reaction in patients with gastric cancer treated with oxaliplatin, but there is no objective biomarkers for changes in OIPN in patients after multiple rounds of chemotherapy. This research aimed to identify serum metabolic biomarkers using longitudinal untargeted metabolomics for early detection of OIPN progression in gastric cancer patients receiving repeated chemotherapy. Methods: Eighty-four serum samples of the same gastric cancer patient (n=42) before and after receiving oxaliplatin chemotherapy twice were collected. The metabolic profiles of serum samples were acquired using an untargeted metabolomics approach based on ultra-high-performance liquid chromatography-Q-Exactive Orbitrap tandem mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS/MS). Multivariate statistical analysis, receiver operating characteristic (ROC) curve analysis, SHapley Additive exPlanations (SHAP) analysis, and pathway enrichment analysis were used to identify potential biomarkers and metabolic pathways. Results: A total of 16 differentially expressed metabolites (DEMs) were screened in discovery set, which belonged to amino acids and derivatives, lipids and derivatives, organic acids and derivatives, and others, mainly involved in amino acid metabolism, lipid metabolism, and nervous system metabolism. Four DEMs (including norepinephrine, 9,10-DHOME, 5-hydroxyindoleacetic acid, and procollagen 5-hydroxy-lysine) showed certain predictive ability for OIPN in the same gastric cancer patient before and after receiving oxaliplatin chemotherapy twice. Thirty-three DEMs were discovered in validation set, notably, norepinephrine emerged as a metabolite exhibiting consistent and notable statistical differences in both the discovery and validation sets. Conclusions: These findings demonstrate the alterations of serum metabolic profiles in patients before and after receiving oxaliplatin chemotherapy, which may deliver valuable biomarkers for early identification and outcome prediction of OIPN progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.